FRESENIUS KABI AUSTRIA GMBH (AUSTRIA)🇸🇬 Health Sciences Authority
Approval Date
May 12, 1993
Approval ID
2aba4b8ca96cc2fd
Company
FRESENIUS KABI AUSTRIA GMBH (AUSTRIA)
Type
Therapeutic
Approval Details
Approval Id
2aba4b8ca96cc2fd
Drug Name
VAMINOLACT INTRAVENOUS SOLUTION
Product Name
VAMINOLACT INTRAVENOUS SOLUTION
Approval Number
SIN07428P
Approval Date
1993-05-12
Registrant
FRESENIUS KABI (SINGAPORE) PTE LTD
Licence Holder
FRESENIUS KABI (SINGAPORE) PTE LTD
Drug Type
Therapeutic
Forensic Classification
GENERAL SALE LIST
Dosage Form
INJECTION
Dosage
<p><strong>Dosage and administration</strong><br>
Recommended dosage</p>
<img src="/TGIF/Vaminolact-Table1.png" alt="Vaminolact Dosage Table 1" /><br><br>
<p>* The dosage should be gradually increased to this value during the first week of life and the infusion should preferably be given continuously over 24 hours.</p>
<p>** The duration of infusion should be at least 8 hours.</p>
<p><strong>Administration</strong><br>
Vaminolact may be infused into the same central of peripheral vein as glucose and fat emulsion by means of a Y-connector near the infusion site.<br>
Discard any unused contents.</p>
Route Of Administration
INTRAVENOUS
Indication Info
<p><strong>Indications</strong><br>
Vaminolact is indicated as a source of amino acids for protein synthesis and of taurine in infants and children requiring intravenous nutrition.</p>
Contraindications
<p><strong>Contraindications</strong><br>
Vaminolact is contra-indicated in patients with inborn errors of amino acid metabolism, irreversible liver damage and in severe uremia when dialysis facilities are not available.</p>
